A Cohort Study in Intensive Care Units: Health Decisions Related to Blood Transfusion during the COVID-19 Pandemic

• Published in: Journal of clinical medicine Vol. 11; no. 15; p. 4396
• Main Authors: Juárez-Vela, Raúl, García-Erce, José Antonio, Gea-Caballero, Vicente, Ruiz de Viñaspre-Hernandez, Regina, Santos-Sánchez, José Ángel, Sánchez-González, Juan Luis, Andrés-Esteban, Eva María, Czapla, Michał, Tejada, Clara Isabel, Nanwani-Nanwani, Kapil Laxman, Serrano-Lázaro, Ainhoa, Quintana-Díaz, Manuel
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 28.07.2022; MDPI
• Subjects: Blood transfusions; Clinical medicine; Cohort analysis; COVID-19; Intensive care; Mortality; Spain; critical care; blood transfusion; coronavirus infections; patient blood management; hemorrhage
• ISSN: 2077-0383; 2077-0383
• DOI: 10.3390/jcm11154396

Critically ill polytrauma patients with hemorrhage require a rapid assessment to initiate hemostatic resuscitation in the shortest possible time with the activation of a massive transfusion or a critical hemorrhage management protocol. The hospital reality experienced during the COVID-19 pandemic in all countries was critical, as it was in Spain; according to the data published daily by the Ministry of Health on its website, during the period of this study, the occupancy rate of intensive care units (ICUs) by patients diagnosed with the novel coronavirus disease (COVID-19) rose to 23.09% in Spain, even reaching 45.23% at the end of January 2021. We aimed to analyze the changes observed during the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic period regarding the effectiveness of Spanish ICUs in terms of mortality reduction. We present a cross-sectional study that compares two cohorts of patients admitted to ICUs across all autonomous communities of Spain with a diagnosis of polytrauma. Results: Only age was slightly higher at admission during the first wave of the pandemic (47.74 ± 18.65 vs. 41.42 ± 18.82 years, = 0.014). The transfusion rate during the pandemic increased by 10.4% compared to the previous stage ( = 0.058). Regarding hemostatic components, the use of tranexamic acid increased from 1.8% to 10.7% and fibrinogen concentrates from 0.9% to 1.9%. In the case of prothrombin complex concentrates, although there was a slight increase in their use, there were no significant differences during the pandemic compared to the previous period. Conclusion: Mortality showed no difference before and during the pandemic, despite the observed change in the transfusion policy. In summary, the immediate and global implementation of patient blood management (PBM) based on clinical transfusion algorithms should be mandatory in all hospitals in our country.